GSK's Stiefel to pay $226M for global rights to Basilea's eczema drug Toctino
This article was originally published in Scrip
Executive Summary
Skin care specialist Stiefel, a GlaxoSmithKline company, has obtained the exclusive worldwide rights for Basilea Pharmaceuticals' marketed hand eczema treatment, Toctino (alitretinoin), for £146 million ($226 million) in cash, with £50 million of cream on top if the US FDA approves the product. Basilea says it will now focus on anti-infectives and cancer.